In the first-line (1L) treatment of r/m PD-L1+ HNSCC, petosemtamab added to standard pembrolizumab therapy demonstrated a 67% confirmed ORR in 24 evaluable patients, with robust responses across PD-L1 tumor levels and human papillomavirus status [57]. The gene discussed is CD274; the disease is neoplasm.